Literature DB >> 9697996

Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model.

J M Cruzado1, J Torras, M Riera, N Lloberas, I Herrero, E Condom, J Martorell, J Alsina, J M Grinyó.   

Abstract

In pig to human discordant xenotransplantation, PAF may contribute to the pathogenesis of hyperacute xenograft rejection (HXR). We examined the release of PAF and the effect of a PAF receptor antagonist (BN 52021) on HXR in a pig kidney-human blood xenoperfusion model. Pig kidneys were perfused with porcine blood (AUTO group, n = 5), human blood (HETER group, n = 6) or human blood plus BN 52021 (BN group, n = 4), respectively. In contrast to HETER kidneys that never produced urine and were rejected in 15-30 min, the administration of BN 52021 induced a partial recovery of glomerular filtration rate and allowed kidneys to function until the end of the study. The release of PAF and soluble P-selectin, as well as endothelial P-selectin expression and tissue myeloperoxidase (MPO), were much higher in the HETER than in the AUTO group. HETER and BN kidneys displayed similar natural xenoantibody titres, CH50, PAF, soluble P-selectin as well as renal immunoglobulin (IgM, IgG, IgA) and complement (C3, C1q) deposition. However, HETER kidneys displayed a full histologic picture of HXR (mainly interstitial haemorrhage and vascular microthrombi) and BN kidneys had only endothelial cell swelling. Also, BN 52021 administration attenuated glomerular and vascular P-selectin expression and renal tissue MPO activity. We conclude that in the pig kidney-human blood xenoperfusion model, PAF is produced in higher amounts than in the pig kidney-pig blood autologous combination. The administration of BN 52021 exerts a protective effect by means of attenuating the acute inflammatory response and blocking vascular microthrombi formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697996      PMCID: PMC1905009          DOI: 10.1046/j.1365-2249.1998.00634.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface.

Authors:  R Hattori; K K Hamilton; R P McEver; P J Sims
Journal:  J Biol Chem       Date:  1989-05-25       Impact factor: 5.157

3.  Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation.

Authors:  G I Johnston; R G Cook; R P McEver
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

4.  PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells.

Authors:  R Bonfanti; B C Furie; B Furie; D D Wagner
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

5.  Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures.

Authors:  F Bussolino; G Camussi; M Aglietta; P Braquet; A Bosia; G Pescarmona; F Sanavio; N D'Urso; P C Marchisio
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

6.  Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response.

Authors:  L Makowka; C Miller; P Chapchap; L Podesta; C Pan; D Pressley; V Mazzaferro; C O Esquivel; S Todo; B Banner
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

7.  Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140.

Authors:  R Hattori; K K Hamilton; R D Fugate; R P McEver; P J Sims
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

8.  Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.

Authors:  R Korth; M Hirafuji; C L Keraly; D Delautier; J Bidault; J Benveniste
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

9.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.

Authors:  P P Bradley; D A Priebat; R D Christensen; G Rothstein
Journal:  J Invest Dermatol       Date:  1982-03       Impact factor: 8.551

10.  Platelet activating factor and leukotriene B4 induce hyperpolarization of human endothelial cells but depolarization of neutrophils.

Authors:  R Lerner; P Lindström; J Palmblad
Journal:  Biochem Biophys Res Commun       Date:  1988-06-16       Impact factor: 3.575

View more
  4 in total

1.  Interleukin-8 mediates neutrophil-endothelial interactions in pig-to-human xenogeneic models.

Authors:  Beth M French; Selin Sendil; Krishna Mohan Sepuru; Jolene Ranek; Lars Burdorf; Donald Harris; Emily Redding; Xiangfei Cheng; Christopher T Laird; Yuming Zhao; Benjamin Cerel; Krishna Rajarathnam; Richard N Pierson; Agnes M Azimzadeh
Journal:  Xenotransplantation       Date:  2018-02-09       Impact factor: 3.907

Review 2.  Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases.

Authors:  Yulong Liu; Lisa B E Shields; Zhongwen Gao; Yuanyi Wang; Yi Ping Zhang; Tianci Chu; Qingsan Zhu; Christopher B Shields; Jun Cai
Journal:  Mol Neurobiol       Date:  2016-09-09       Impact factor: 5.590

Review 3.  Differences in platelet aggregometers to study platelet function and coagulation dysregulation in xenotransplantation.

Authors:  Abdulkadir Isidan; Angela M Chen; Kutay Saglam; Sezai Yilmaz; Wenjun Zhang; Ping Li; Burcin Ekser
Journal:  Xenotransplantation       Date:  2020-09-18       Impact factor: 3.907

Review 4.  The Innate Cellular Immune Response in Xenotransplantation.

Authors:  Akira Maeda; Shuhei Kogata; Chiyoshi Toyama; Pei-Chi Lo; Chizu Okamatsu; Riho Yamamoto; Kazunori Masahata; Masafumi Kamiyama; Hiroshi Eguchi; Masahito Watanabe; Hiroshi Nagashima; Hiroomi Okuyama; Shuji Miyagawa
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.